Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Given Consensus Rating of “Hold” by Brokerages

Shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) have received a consensus rating of “Hold” from the five brokerages that are covering the firm, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell rating and three have given a buy rating to the company. The average 1-year target price among brokers that have covered the stock in the last year is $5.50.

A number of research analysts recently issued reports on the stock. Weiss Ratings upgraded shares of Maravai LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, May 29th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a $6.00 price objective on shares of Maravai LifeSciences in a report on Friday, May 8th. Wells Fargo & Company raised their price objective on shares of Maravai LifeSciences from $4.50 to $5.50 and gave the stock an “overweight” rating in a report on Friday, May 8th. UBS Group reissued a “reduce” rating on shares of Maravai LifeSciences in a report on Wednesday, June 3rd. Finally, Wall Street Zen raised shares of Maravai LifeSciences from a “hold” rating to a “buy” rating in a report on Saturday, May 23rd.

Insiders Place Their Bets

In other Maravai LifeSciences news, General Counsel Kurt Oreshack sold 25,000 shares of the firm’s stock in a transaction that occurred on Tuesday, June 9th. The shares were sold at an average price of $5.06, for a total transaction of $126,500.00. Following the sale, the general counsel owned 360,767 shares of the company’s stock, valued at approximately $1,825,481.02. This trade represents a 6.48% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 2.49% of the company’s stock.

Institutional Trading of Maravai LifeSciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in MRVI. Wellington Management Group LLP acquired a new stake in Maravai LifeSciences during the fourth quarter worth approximately $7,670,000. General American Investors Co. Inc. increased its holdings in shares of Maravai LifeSciences by 1,062.2% in the 4th quarter. General American Investors Co. Inc. now owns 1,585,316 shares of the company’s stock valued at $5,152,000 after acquiring an additional 1,448,907 shares during the period. Millennium Management LLC increased its holdings in shares of Maravai LifeSciences by 308.7% in the 4th quarter. Millennium Management LLC now owns 1,797,052 shares of the company’s stock valued at $5,840,000 after acquiring an additional 1,357,349 shares during the period. First Eagle Investment Management LLC raised its position in Maravai LifeSciences by 299.0% in the 4th quarter. First Eagle Investment Management LLC now owns 1,799,336 shares of the company’s stock valued at $5,848,000 after purchasing an additional 1,348,405 shares during the last quarter. Finally, Marshall Wace LLP boosted its stake in Maravai LifeSciences by 52.3% during the 4th quarter. Marshall Wace LLP now owns 2,000,278 shares of the company’s stock worth $6,501,000 after purchasing an additional 687,253 shares during the period. Institutional investors and hedge funds own 50.25% of the company’s stock.

Maravai LifeSciences Stock Up 2.2%

Shares of Maravai LifeSciences stock opened at $6.26 on Friday. Maravai LifeSciences has a 52-week low of $1.99 and a 52-week high of $6.29. The company has a 50 day moving average of $4.53 and a 200 day moving average of $3.77. The company has a quick ratio of 4.96, a current ratio of 5.91 and a debt-to-equity ratio of 0.72. The company has a market capitalization of $1.61 billion, a P/E ratio of -8.81 and a beta of 0.72.

Maravai LifeSciences (NASDAQ:MRVI) last issued its quarterly earnings results on Thursday, May 7th. The company reported $0.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.06. Maravai LifeSciences had a negative net margin of 51.07% and a negative return on equity of 17.87%. The company had revenue of $65.84 million during the quarter, compared to the consensus estimate of $53.00 million. As a group, research analysts forecast that Maravai LifeSciences will post -0.2 EPS for the current fiscal year.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.